Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Jabak Discussed with the Syndicate of Hospitals Owners the Health Sector Issues and Received an Invitation to Attend the Arab Hospitals Forum in Cairo

 
The Minister of Public Health Jamil Jabak received a delegation from the private hospitals owners syndicate headed by Sleiman Haroun, in the presence of MP Fadi Alama. During a meeting, hospitals matters and the ways to find solutions for the problems of the citizens and the hospitals’ owners were discussed.
 
“We consider them as an integral part of the hospitalization sector in Lebanon and a key partner in the health care and medical sector in Lebanon,” Jabak told the delegation.
 
Dr. Jabak said that the meeting tackled the problems of the syndicate and mentioned that the ministry would work to find solutions to these problems in no time.
 
Haroun

Haroun stated that the visit aimed at congratulating Dr. Jabak for taking office at the Ministry. “The meeting provided an opportunity to consider the matters that need to be dealt with on the long term,” Jabak added.
 
“The delegation noticed Minister Jabak’s concern for the hospitals as much as for the patient and the need to provide him with the necessary services. It was agreed to activate the current scientific mechanism related to the admission of the patient to the emergency room at the hospitals in order to prevent any issues that might arise while admission,” Haroun said.
 
“The syndicate’s delegation asked the Minister of Public health to find solutions for the delay in the settlement of the amounts owed to the hospitals,” Haroun added.
 
Arab Hospitals Federation

Jabak then met with a delegation from the Arab Hospitals Federation that invited him to attend the “Arab Hospitals Federation Forum in Cairo” that will be held in conjunction with the Council of Arab Ministers of Health on 27 and 28 February. The delegation also invited him to attend the Arab Hospitals Federation Conference” that will be held next 10 and 11 April in Kuwait.
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
N02BE01 TYLENOL B Paracetamol - 100mg 100mg Suppository 190,826 L.L
N02BE01 TYLENOL B Paracetamol - 200mg 200mg Suppository 235,172 L.L
J01MA12 TAVANIC B Levofloxacin - 500mg 500mg Tablet, film-scored 1,150,329 L.L
D07XC04 TRAVOCORT B Diflucortolone valerate - 0.1%, Isoconazole nitrate - 1% Cream 435,405 L.L
J07CA02 TETRAXIM (Vaccin Diphterique, tetanique, coquelucheux acellulaire et Poliomyelitique inactivé adsorbé) B Diphteria toxoid purified - ?30IU, Tetanus toxoid purified - ?40IU, Poliomyelitis virus type 1 inactivated - 40D.U., Poliomyelitis virus type 2 inactivated - 8D.U., Poliomyelitis virus type 3 inactivated - 32D.U., Bordetella Pertussis Antigens: toxoid - 25mcg, Bordetella Pertussis Antigens: filamentous haemagglutinin - 25mcg Injectable suspension 1,628,737 L.L
N02BE01 TYLENOL B Paracetamol - 350mg 350mg Suppository 239,204 L.L
H01AB01 THYROGEN BioHuman Thyrotropin alfa - 0.9mg 0.9mg Injectable lyophilised powder for solution+diluent 65,558,997 L.L
J06BB02 TETAGAM P BioHuman Human Tetanus Immunoglobulin - 250IU/ml 250IU/ml Injectable solution 2,958,325 L.L
J06BB02 TETANUS GAMMA BioHuman Human Tetanus Immunoglobulin - 250IU/ml 250IU/ml Injectable solution 3,077,399 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 0.75mg/0.5ml 0.75mg/0.5ml Injectable solution 10,165,201 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 1.5mg/0.5ml 1.5mg/0.5ml Injectable solution 10,165,201 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 3mg/0.5ml 3mg/0.5ml Injectable solution 10,165,201 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 4.5mg 4.5mg/0.5ml Injectable solution 10,165,201 L.L
L01FA01 TRUXIMA BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 31,060,158 L.L
L01FA01 TRUXIMA BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 69,144,591 L.L
L01FD01 TRASTUREL BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 52,047,114 L.L
L01FD01 TRAZIMERA BioTech Trastuzumab - 440mg 440mg Injectable powder for solution+solvent 75,295,202 L.L
L01FD01 TRAZIMERA BioTech Trastuzumab - 150mg 150mg Injectable powder for solution 28,550,630 L.L
L04AC13 TALTZ BioTech Ixekizumab - 80mg/ml 80mg/ml Injectable solution 85,080,792 L.L
L04AC16 TREMFYA BioTech Guselkumab - 100mg/ml 100mg/ml Injectable solution 190,195,151 L.L
L04AC16 TREMFYA BioTech Guselkumab - 100mg/ml 100mg/ml Injectable solution 190,195,151 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution 375,054,619 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution 375,054,619 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1875mg/15ml 1875mg/15ml Injectable solution 375,054,619 L.L
A10AE04 TOUJEO BioTech Insulin glargine - 300Units/ml 300Units/ml Injectable solution 4,559,658 L.L
A10AE06 TRESIBA BioTech Insulin degludec - 100IU/ml 100IU/ml Injectable solution 6,857,628 L.L
B06AC05 TAKHZYRO BioTech Lanadelumab - 300mg/2ml Injectable solution 1,204,227,927 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution L.L
L01FD01 TRASTUREL BioTech Trastuzumab - 440mg L.L
L04AA04 THYMOGLOBULINE 5mg/ml BioTech Rabbit anti-human thymocyte immunoglobulin - 25mg/5ml 25mg/5ml Injectable powder for solution 21,092,764 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025